SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001144204-19-005052
Filing Date
2019-02-05
Accepted
2019-02-05 16:40:49
Documents
2
Group Members
ARUN KUMAR PILLAIGHIATH M. SUKHTIAN

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tv512232_sc13da.htm SC 13D/A 108890
2 EXHIBIT 1 tv512232_ex99-1.htm EX-99.1 5203
  Complete submission text file 0001144204-19-005052.txt   115774
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Subject) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-89495 | Film No.: 19568483
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877
Business Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877 962 6 582 7999
BioLexis Pte Ltd. (Filed by) CIK: 0001716335 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A